Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 2
1999 2
2000 3
2001 1
2002 3
2003 4
2004 3
2005 3
2006 6
2007 5
2008 7
2009 5
2010 4
2011 6
2012 4
2013 6
2014 7
2015 11
2016 10
2017 6
2018 6
2019 7
2020 8
2021 7
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

112 results
Results by year
Filters applied: . Clear all
Page 1
Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis.
Skendros P, Mitsios A, Chrysanthopoulou A, Mastellos DC, Metallidis S, Rafailidis P, Ntinopoulou M, Sertaridou E, Tsironidou V, Tsigalou C, Tektonidou M, Konstantinidis T, Papagoras C, Mitroulis I, Germanidis G, Lambris JD, Ritis K. Skendros P, et al. J Clin Invest. 2020 Nov 2;130(11):6151-6157. doi: 10.1172/JCI141374. J Clin Invest. 2020. PMID: 32759504 Free PMC article. Clinical Trial.
COVID-19 serum induced complement activation in vitro, consistent with high complement activity in clinical samples. Complement C3 inhibition with compstatin Cp40 disrupted TF expression in neutrophils. In conclusion, we provide a mechanistic basis for a pivotal role of co …
COVID-19 serum induced complement activation in vitro, consistent with high complement activity in clinical samples. Complement C3 inhibitio …
Clinical promise of next-generation complement therapeutics.
Mastellos DC, Ricklin D, Lambris JD. Mastellos DC, et al. Nat Rev Drug Discov. 2019 Sep;18(9):707-729. doi: 10.1038/s41573-019-0031-6. Epub 2019 Jul 19. Nat Rev Drug Discov. 2019. PMID: 31324874 Free PMC article. Review.
Innate immune responses to trauma.
Huber-Lang M, Lambris JD, Ward PA. Huber-Lang M, et al. Nat Immunol. 2018 Apr;19(4):327-341. doi: 10.1038/s41590-018-0064-8. Epub 2018 Mar 5. Nat Immunol. 2018. PMID: 29507356 Free PMC article. Review.
Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.
Mastellos DC, Pires da Silva BGP, Fonseca BAL, Fonseca NP, Auxiliadora-Martins M, Mastaglio S, Ruggeri A, Sironi M, Radermacher P, Chrysanthopoulou A, Skendros P, Ritis K, Manfra I, Iacobelli S, Huber-Lang M, Nilsson B, Yancopoulou D, Connolly ES, Garlanda C, Ciceri F, Risitano AM, Calado RT, Lambris JD. Mastellos DC, et al. Clin Immunol. 2020 Nov;220:108598. doi: 10.1016/j.clim.2020.108598. Epub 2020 Sep 19. Clin Immunol. 2020. PMID: 32961333 Free PMC article.
Here we compare the efficacy of the C5-targeting monoclonal antibody eculizumab with that of the compstatin-based C3-targeted drug candidate AMY-101 in small independent cohorts of severe COVID-19 patients. ...
Here we compare the efficacy of the C5-targeting monoclonal antibody eculizumab with that of the compstatin-based C3-targeted drug ca …
Compstatin: a complement inhibitor on its way to clinical application.
Ricklin D, Lambris JD. Ricklin D, et al. Adv Exp Med Biol. 2008;632:273-92. doi: 10.1007/978-0-387-78952-1_20. Adv Exp Med Biol. 2008. PMID: 19025129 Free PMC article. Review.
Furthermore, the release of a co-crystal structure of compstatin with C3c allows a detailed insight into the binding mode and paves the way to the rational design of peptides and mimetics with improved activity. Considering the new incentives and the promising pre-clinical …
Furthermore, the release of a co-crystal structure of compstatin with C3c allows a detailed insight into the binding mode and paves t …
Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation.
Nilsson B, Larsson R, Hong J, Elgue G, Ekdahl KN, Sahu A, Lambris JD. Nilsson B, et al. Blood. 1998 Sep 1;92(5):1661-7. Blood. 1998. PMID: 9716594 Free article.
Compstatin effectively inhibited the generation of C3a and sC5b-9 and the binding of C3/ C3 fragments to the polymer surface. ...These data show that complement activation, leading to activation and binding of PMNs to the biomaterial surface, can be abolished by the additi
Compstatin effectively inhibited the generation of C3a and sC5b-9 and the binding of C3/ C3 fragments to the polymer surface. ...Thes
Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention.
Mastellos DC, Yancopoulou D, Kokkinos P, Huber-Lang M, Hajishengallis G, Biglarnia AR, Lupu F, Nilsson B, Risitano AM, Ricklin D, Lambris JD. Mastellos DC, et al. Eur J Clin Invest. 2015 Apr;45(4):423-40. doi: 10.1111/eci.12419. Epub 2015 Mar 9. Eur J Clin Invest. 2015. PMID: 25678219 Free PMC article. Review.
Indeed, the introduction of the first complement-targeting drugs has reignited a vibrant interest in the clinical translation of complement-based inhibitors. Compstatin was discovered as a cyclic peptide that inhibits complement activation by binding C3 and interfering wit …
Indeed, the introduction of the first complement-targeting drugs has reignited a vibrant interest in the clinical translation of complement- …
Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency.
Qu H, Magotti P, Ricklin D, Wu EL, Kourtzelis I, Wu YQ, Kaznessis YN, Lambris JD. Qu H, et al. Mol Immunol. 2011 Jan;48(4):481-9. doi: 10.1016/j.molimm.2010.10.004. Epub 2010 Nov 9. Mol Immunol. 2011. PMID: 21067811 Free PMC article.
Compstatin is a 13-residue disulfide-bridged peptide that inhibits a key step in the activation of the human complement system. Compstatin and its derivatives have shown great promise for the treatment of many clinical disorders associated with unbalanced complement
Compstatin is a 13-residue disulfide-bridged peptide that inhibits a key step in the activation of the human complement system. Co
Prolonged intraocular residence and retinal tissue distribution of a fourth-generation compstatin-based C3 inhibitor in non-human primates.
Hughes S, Gumas J, Lee R, Rumano M, Berger N, Gautam AK, Sfyroera G, Chan AL, Gnanaguru G, Connor KM, Kim BJ, Dunaief JL, Ricklin D, Hajishengallis G, Yancopoulou D, Reis ES, Mastellos DC, Lambris JD. Hughes S, et al. Clin Immunol. 2020 May;214:108391. doi: 10.1016/j.clim.2020.108391. Epub 2020 Mar 27. Clin Immunol. 2020. PMID: 32229292 Free PMC article.
In this regard, a PEGylated second-generation derivative of the compstatin family of C3-targeted inhibitors is currently in late-stage clinical development as a treatment option for geographic atrophy, an advanced form of AMD which lacks approved therapy. ...Here we report …
In this regard, a PEGylated second-generation derivative of the compstatin family of C3-targeted inhibitors is currently in late-stag …
112 results